Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TREPROSTINIL Cause Intentional product use issue? 254 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 254 reports of Intentional product use issue have been filed in association with TREPROSTINIL (TYVASO). This represents 0.3% of all adverse event reports for TREPROSTINIL.

254
Reports of Intentional product use issue with TREPROSTINIL
0.3%
of all TREPROSTINIL reports
7
Deaths
66
Hospitalizations

How Dangerous Is Intentional product use issue From TREPROSTINIL?

Of the 254 reports, 7 (2.8%) resulted in death, 66 (26.0%) required hospitalization, and 1 (0.4%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TREPROSTINIL. However, 254 reports have been filed with the FAERS database.

What Other Side Effects Does TREPROSTINIL Cause?

Dyspnoea (16,348) Headache (14,051) Diarrhoea (11,335) Nausea (10,320) Cough (8,945) Fatigue (7,440) Dizziness (7,405) Infusion site pain (5,169) Vomiting (5,097) Death (4,764)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which TREPROSTINIL Alternatives Have Lower Intentional product use issue Risk?

TREPROSTINIL vs TREPROSTINIL DIOLAMINE TREPROSTINIL vs TRETINOIN TREPROSTINIL vs TRIAMCINOLONE TREPROSTINIL vs TRIAMCINOLONE ACETONIDE TREPROSTINIL vs TRIAMCINOLONE HEXACETONIDE

Related Pages

TREPROSTINIL Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue TREPROSTINIL Demographics